This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
AbbVie (ABBV) Stock Moves 0.47%: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed the most recent trading day at $94.60, moving +0.47% from the previous trading session.
Pharma Stock Roundup: PFE, LLY Get Approval for New Drugs, Novartis to Cut Jobs
by Zacks Equity Research
FDA grants approval to Lilly's (LLY) Emgality for migraine and Pfizer's (PFE) Vizimpro for an advanced lung cancer indication. Novartis (NVS) to cut more than 2,000 jobs in Switzerland and U.K
Gilead (GILD) to Launch Generics for Leading HCV Treatments
by Zacks Equity Research
Given the persistent decline in HCV sales, Gilead (GILD) plans to launch authorized generic versions of its leading hepatitis C virus (HCV) treatments, Epclusa and Harvoni.
AbbVie/Roche's Leukemia Drugs Combo Gets CHMP Backing in EU
by Zacks Equity Research
The CHMP gives positive opinion for combination use of AbbVie's (ABBV) Venclexta and Roche's Rituxan for relapsed/refractory CLL in patients who have received at least one prior therapy.
AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, AbbVie (ABBV) closed at $92.05, marking a -0.51% move from the previous day.
Pfizer's Pneumococcal Vaccine Gets Breakthrough Therapy Status
by Zacks Equity Research
Pfizer's (PFE) investigational pneumococcal vaccine PF-06651600 gets Breakthrough Therapy designation from the FDA for prevention of invasive disease and pneumonia.
Company News For Sep 20, 2018
by Zacks Equity Research
Companies In The News are: TLRY,FB,CPRT,ABBV
Bristol-Myers' MM Drug Empliciti Application Validated by EMA
by Zacks Equity Research
Bristol-Myers' (BMY) application for multiple myeloma drug, Empliciti gets validated in Europe.
AbbVie Faces California Insurance Department Suit for Humira
by Zacks Equity Research
AbbVie's (ABBV) shares fall on a lawsuit by California insurance department accusing it of giving illegal kickbacks to doctors for prescribing Humira.
Pfizer's Skin Disease Candidates Positive in Mid-Stage Study
by Zacks Equity Research
Pfizer's (PFE) JAK inhibitor candidates -- PF-06651600 and PF-06700841 -- demonstrate improvements in moderate to severe alopecia areata patients in a phase II study.
The Zacks Analyst Blog Highlights: JPMorgan, Mastercard, AbbVie, CVS Health and Estee Lauder
by Zacks Equity Research
The Zacks Analyst Blog Highlights: JPMorgan, Mastercard, AbbVie, CVS Health and Estee Lauder
Pharma/Biotech Stocks to Watch This Prostate Cancer Month
by Zacks Equity Research
Here we highlight a few companies that are focused on developing treatments for prostate cancer.
Roche's Child Arthritis Drug's New Formulation Gets FDA Nod
by Zacks Equity Research
Roche (RHHBY) gets FDA approval for the subcutaneous formulation of Actemra for the treatment of active systemic juvenile idiopathic arthritis in patients aged two years or older.
Top Stock Reports for JPMorgan, Mastercard & AbbVie
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including JPMorgan (JPM), Mastercard (MA) and AbbVie (ABBV).
Should Value Investors Consider AbbVie (ABBV) Stock Now?
by Zacks Equity Research
Let's see if AbbVie Inc. (ABBV) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.
AbbVie Gets FDA Nod for Venclexta Label Expansion in Leukemia
by Zacks Equity Research
AbbVie (ABBV) gets FDA approval to include MRD-negativity (undetectable disease) data from phase III MURANO study on the label of Venclexta.
Vertex Completes Enrollment in Triple Combination Studies
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) completes enrollment in two phase III studies evaluating VX-659 triple combination regimen in CF patients. Data is expected in the fourth quarter of 2018.
Lilly, Teva, Pfizer & Others Await FDA Decisions in September
by Kinjel Shah
FDA grants approval to 34 new treatments this year so far.
Pfizer's Skin Disease Drug Gets Breakthrough Therapy Status
by Zacks Equity Research
Pfizer's (PFE) investigational oral JAK3 inhibitor PF-06651600 gets Breakthrough Therapy designation from the FDA for alopecia areata.
Vertex Inks Reimbursement Agreement for Orkambi in Australia
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) finalizes a reimbursement agreement with Australian government, which will improve the access to the drug.
Pharma Stock Roundup: Approval of NVS & ABBV Cancer Drugs, MRK's HIV Drug in Focus
by Zacks Equity Research
Novartis (NVS) & AbbVie (ABBV) get cancer approvals. Merck (MRK) gets FDA nod for two new HIV medicines.
4 Large Cap Pharma Stocks in Focus on Robust Cancer Pipeline
by Kinjel Shah
We discuss four pharma giants, which possess the industry's strongest oncology pipeline portfolios.
AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed at $97.30 in the latest trading session, marking a -0.84% move from the prior day.
AbbVie's Imbruvica Combo Gets FDA Nod for Rare Lymphoma
by Zacks Equity Research
AbbVie's (ABBV) cancer drug Imbruvica gets FDA approval for use in combination with Roche's Rituxan for Waldenstrom's macroglobulinemia (WM), a rare form of Non-Hodgkin's lymphoma.
AbbVie (ABBV) Up 3.7% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
AbbVie (ABBV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.